NL8203587A - Tricyclische chinazolinonen, werkwijzen voor hun bereiding, farmaceutische preparaten die ze bevatten en hun therapeutische toepassing. - Google Patents
Tricyclische chinazolinonen, werkwijzen voor hun bereiding, farmaceutische preparaten die ze bevatten en hun therapeutische toepassing. Download PDFInfo
- Publication number
- NL8203587A NL8203587A NL8203587A NL8203587A NL8203587A NL 8203587 A NL8203587 A NL 8203587A NL 8203587 A NL8203587 A NL 8203587A NL 8203587 A NL8203587 A NL 8203587A NL 8203587 A NL8203587 A NL 8203587A
- Authority
- NL
- Netherlands
- Prior art keywords
- group
- carbon atoms
- formula
- alkyl group
- hydrogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 23
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 6
- 230000001225 therapeutic effect Effects 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 81
- 125000004432 carbon atom Chemical group C* 0.000 claims description 61
- 229910052801 chlorine Inorganic materials 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- 239000000460 chlorine Substances 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 23
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 239000002585 base Substances 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 239000012458 free base Substances 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 108090000839 GABA-A Receptors Proteins 0.000 description 8
- 102000004300 GABA-A Receptors Human genes 0.000 description 8
- 229960002200 flunitrazepam Drugs 0.000 description 7
- 229940049706 benzodiazepine Drugs 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 5
- 229940113088 dimethylacetamide Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000003204 tranquilizing agent Substances 0.000 description 5
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005222 photoaffinity labeling Methods 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- RELMFMZEBKVZJC-UHFFFAOYSA-N 1,2,3-trichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1Cl RELMFMZEBKVZJC-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- -1 dimethyl acetate amide Chemical class 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940125725 tranquilizer Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- UUKHHDQBZOVMIY-UHFFFAOYSA-N 1-ethyl-2-methylsulfanyl-4,5-dihydroimidazole Chemical compound CCN1CCN=C1SC UUKHHDQBZOVMIY-UHFFFAOYSA-N 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- SAARQEYWLYTQFL-UHFFFAOYSA-N 2,6-dichloro-4-(2-chloroethoxy)quinazoline Chemical compound C1=C(Cl)C=C2C(OCCCl)=NC(Cl)=NC2=C1 SAARQEYWLYTQFL-UHFFFAOYSA-N 0.000 description 1
- IFXKXCLVKQVVDI-UHFFFAOYSA-N 2-amino-5-chlorobenzoic acid Chemical compound NC1=CC=C(Cl)C=C1C(O)=O IFXKXCLVKQVVDI-UHFFFAOYSA-N 0.000 description 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000006012 2-chloroethoxy group Chemical group 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 101150099834 Eqtn gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 108010045196 flunitrazepam receptor Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 229960002456 hexobarbital Drugs 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ANORDWOIBSUYBN-UHFFFAOYSA-N n-chloro-1-phenylmethanamine Chemical compound ClNCC1=CC=CC=C1 ANORDWOIBSUYBN-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30248681A | 1981-09-16 | 1981-09-16 | |
| US30248381A | 1981-09-16 | 1981-09-16 | |
| US30248581A | 1981-09-16 | 1981-09-16 | |
| US30248481A | 1981-09-16 | 1981-09-16 | |
| US30248381 | 1981-09-16 | ||
| US30248681 | 1981-09-16 | ||
| US30248481 | 1981-09-16 | ||
| US30248581 | 1981-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8203587A true NL8203587A (nl) | 1983-04-18 |
Family
ID=27501816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8203587A NL8203587A (nl) | 1981-09-16 | 1982-09-16 | Tricyclische chinazolinonen, werkwijzen voor hun bereiding, farmaceutische preparaten die ze bevatten en hun therapeutische toepassing. |
Country Status (12)
| Country | Link |
|---|---|
| AU (1) | AU8838582A (sv) |
| DE (1) | DE3233766A1 (sv) |
| DK (1) | DK410782A (sv) |
| ES (1) | ES515693A0 (sv) |
| FI (1) | FI823207L (sv) |
| FR (1) | FR2512674B1 (sv) |
| GB (1) | GB2105721B (sv) |
| IT (1) | IT1189355B (sv) |
| NL (1) | NL8203587A (sv) |
| NZ (1) | NZ201915A (sv) |
| PT (1) | PT75555B (sv) |
| SE (1) | SE8205256L (sv) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4490371A (en) * | 1983-02-16 | 1984-12-25 | Syntex (U.S.A.) Inc. | N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides |
| US4760065A (en) * | 1986-02-13 | 1988-07-26 | Hardtmann Goetz E | Trifluoromethyl substituted tetracyclic quinazolin-ones having tranquilizing activity |
| CZ281628B6 (cs) * | 1991-07-29 | 1996-11-13 | Warner-Lambert Company | Deriváty chinazolinu a farmaceutické přípravky na jejich bázi |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3631046A (en) * | 1969-05-28 | 1971-12-28 | Sandoz Ag | Tetracyclic quinazolin-ones |
-
1982
- 1982-09-10 FR FR8215474A patent/FR2512674B1/fr not_active Expired
- 1982-09-11 DE DE19823233766 patent/DE3233766A1/de not_active Withdrawn
- 1982-09-13 GB GB08226008A patent/GB2105721B/en not_active Expired
- 1982-09-14 SE SE8205256A patent/SE8205256L/sv not_active Application Discontinuation
- 1982-09-14 DK DK410782A patent/DK410782A/da not_active Application Discontinuation
- 1982-09-14 ES ES515693A patent/ES515693A0/es active Granted
- 1982-09-14 PT PT75555A patent/PT75555B/pt unknown
- 1982-09-14 AU AU88385/82A patent/AU8838582A/en not_active Abandoned
- 1982-09-14 NZ NZ201915A patent/NZ201915A/xx unknown
- 1982-09-15 IT IT49124/82A patent/IT1189355B/it active
- 1982-09-16 NL NL8203587A patent/NL8203587A/nl not_active Application Discontinuation
- 1982-09-16 FI FI823207A patent/FI823207L/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES8402838A1 (es) | 1984-03-01 |
| FR2512674B1 (fr) | 1986-01-10 |
| SE8205256L (sv) | 1983-03-17 |
| GB2105721A (en) | 1983-03-30 |
| FI823207A0 (fi) | 1982-09-16 |
| IT8249124A0 (it) | 1982-09-15 |
| GB2105721B (en) | 1985-11-13 |
| PT75555A (en) | 1982-10-01 |
| ES515693A0 (es) | 1984-03-01 |
| FI823207L (fi) | 1983-03-17 |
| IT1189355B (it) | 1988-02-04 |
| SE8205256D0 (sv) | 1982-09-14 |
| NZ201915A (en) | 1985-11-08 |
| DK410782A (da) | 1983-03-17 |
| FR2512674A1 (fr) | 1983-03-18 |
| AU8838582A (en) | 1983-03-24 |
| PT75555B (en) | 1985-05-31 |
| DE3233766A1 (de) | 1983-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100548853B1 (ko) | 아졸로 트리아진 및 피리미딘 | |
| US6191131B1 (en) | Azolo triazines and pyrimidines | |
| DE69925970T2 (de) | Pyrazolopyrimidinone cGMP PDE5 Inhibitoren zur Behandlung der sexuellen Dysfunktion | |
| DE60016566T2 (de) | Triazolopyridazinderivate als liganden für gaba-rezeptoren | |
| US6124289A (en) | Azolo triazines and pyrimidines | |
| CN102365285B (zh) | 1-杂环基-1，5-二氢-吡唑并[3，4-d]嘧啶-4-酮衍生物及其作为pde9a调节剂的用途 | |
| US6060478A (en) | Azolo triazines and pyrimidines | |
| DE69926665T2 (de) | Azolo-Pyrimidine | |
| US20030139426A1 (en) | Pyrazolopyrimidines as CRF antagonists | |
| JPH10506126A (ja) | 新規なデアザプリン誘導体；ｃｒｆ１特異性リガンドの新規なクラス | |
| CZ20002691A3 (cs) | Triazolopyridazinové deriváty | |
| US6734185B2 (en) | Pyrrolo[3,4-d]pyrimidines as corticotropin releasing factor (CRF) antagonists | |
| FR2766823A1 (fr) | Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique | |
| DE2539131A1 (de) | 6-phenyl-4h-imidazo- eckige klammer auf 1,2-a eckige klammer zu eckige klammer auf 1,4 eckige klammer zu benzodiazepine sowie ein verfahren zu deren herstellung | |
| NL8203587A (nl) | Tricyclische chinazolinonen, werkwijzen voor hun bereiding, farmaceutische preparaten die ze bevatten en hun therapeutische toepassing. | |
| US6949549B2 (en) | Imidazolophthalazine derivatives as ligands for GABAA receptors | |
| JP4194539B2 (ja) | アゾロトリアジン類およびアゾロピリミジン類 | |
| US4028356A (en) | Triazinobenzodiazepines | |
| US20030008885A1 (en) | Azolo triazines and pyrimidines | |
| US7678793B2 (en) | Azolo triazines and pyrimidines | |
| US3996230A (en) | 1-Piperazino-6-(2-pyridyl)-4H-s-triazolo[4,3-a][1,4]benzodiazepines | |
| US4760065A (en) | Trifluoromethyl substituted tetracyclic quinazolin-ones having tranquilizing activity | |
| US4451448A (en) | 1-Substituted tricyclic quinazolinones useful as tranquilizers | |
| CN101027285A (zh) | 制备双环吡唑基化合物的方法 | |
| JPH0784468B2 (ja) | 〔７−（３−二置換されたアミノ）−フエニル〕ピラゾロ〔１，５−ａ〕−ピリミジン類 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |